LGND

Business Context and Reporting Period

Ligand Pharmaceuticals Inc. (Ligand) is a biotechnology company focused on drug discovery and early-stage development. This Form 10-Q covers the quarterly period ended September 30, 2010. The company's business model relies on generating income from research, milestone, and royalty revenues through collaborations with pharmaceutical partners. Key recent strategic actions include the acquisition of Metabasis Therapeutics (January 2010) and Neurogen Corporation (December 2009), and the divestiture of its Oncology and AVINZA product lines, which are reported as discontinued operations.

Key Financial Metrics

Revenue Composition: Royalties accounted for $1.8 million (3 months) and $5.3 million (9 months). Collaborative research and development revenues were $6.0 million (3 months) and $14.3 million (9 months).

Debt and Liquidity: The company reported a working capital deficit of approximately $1.4 million. Total liabilities were $113.7 million, primarily driven by long-term co-promote termination liabilities ($28.6 million) and income tax payable ($29.4 million). The company has no significant long-term debt obligations other than lease termination payments and contingent value rights.

Material Changes vs. Prior Period

• Operating Loss: The company reported a loss from continuing operations of $11.9 million for the three months ended September 30, 2010, compared to an operating income of $0.8 million in the same period in 2009. This reversal is largely due to significant non-recurring costs.
• Lease Exit Costs: A major driver of the loss was $15.9 million in lease exit and termination costs for the three months ended September 30, 2010. This included a $9.7 million charge for the closure of the Cranbury, New Jersey facility and a $5.4 million write-off of property and equipment.
• Revenue Decline: Total revenues decreased slightly to $7.8 million (3 months) from $7.9 million in 2009. Royalty revenue decreased by $1.1 million for the nine-month period, primarily due to lower AVINZA sales, partially offset by increased PROMACTA sales.
• Non-Cash Gains: The company recorded a $2.5 million gain (3 months) and $6.7 million gain (9 months) from the decrease in the liability for Contingent Value Rights (CVRs) associated with the Metabasis acquisition.
• Acquisition Activity: In the nine months ended September 30, 2010, the company acquired Metabasis Therapeutics and certain intellectual property from the Genaera Liquidating Trust, resulting in significant additions to In-Process Research and Development (IPR&D) assets.

Guidance, Outlook, and Risks

Management Commentary: Management believes current cash, cash equivalents, and short-term investments ($24.1 million total) combined with future royalty and milestone revenues will be sufficient to fund operations for at least the next twelve months. The company is committed to spending at least $8.0 million on Metabasis programs within 42 months of the acquisition; approximately $2.1 million has been spent as of September 30, 2010.

Key Risks and Contingencies:

• IRS Dispute: The IRS issued a Notice of Proposed Adjustment (NOPA) for the 2007 tax year, seeking a $71.5 million increase in taxable income and a $4.1 million penalty. Ligand has recorded a $25.1 million liability for uncertain tax positions and $3.8 million for estimated interest. The company is negotiating and has received an extension to file an amended return.
• Revenue Concentration: Royalties from AVINZA and PROMACTA represent a substantial portion of revenue. Any setbacks in sales, regulatory issues, or generic competition (e.g., Actavis and Sandoz patent challenges for AVINZA) could materially impact results.
• Collaboration Dependencies: The company relies on partners (Pfizer, GSK, Roche, etc.) for development and commercialization. Recent terminations of agreements with Trevena and GSK highlight the risk of losing revenue streams.
• Integration Risks: The company faces challenges integrating Neurogen and Metabasis, including incomplete electronic data received from Metabasis which may impact development timelines.
• Stock Split: A 1-for-6 reverse stock split was approved by stockholders in September 2010 and implemented in November 2010.

Investor Verification Checklist

• Verify the status and potential outcome of the IRS audit regarding the 2007 tax year and the associated $25.1 million liability.
• Monitor the progress of the patent infringement lawsuits filed by King against Actavis and Sandoz regarding AVINZA, as a loss could accelerate generic competition.
• Review the development status of key pipeline assets, particularly the Metabasis programs (hepatitis C, diabetes) and the impact of the data deficiencies discovered post-acquisition.
• Assess the sustainability of royalty revenues from AVINZA and PROMACTA given the competitive landscape and potential for partner strategy shifts (e.g., Pfizer's acquisition of King).
• Confirm the company's ability to meet the $8.0 million R&D commitment for Metabasis programs without requiring additional equity financing.